Mundipharma to sell Novartis ophthalmology medicines in Taiwan

A new agreement grants Mundipharma the marketing, sales and distribution rights of Novartis ophthalmology medicines in Taiwan, according to a press release.

The deal follows similar agreements in the Philippines and Thailand.

“Mundipharma is constantly exploring opportunities to increase access to important medicines for the people who need them the most,” Mundipharma CEO Raman Singh said in the release. “This agreement with Novartis is an expansion of an already successful partnership between our two organizations and is another example of how we work with partners to leverage our unique distribution network to address unmet patient needs.”

Under the agreement, Novartis will retain all international development and clinical development responsibilities.

A new agreement grants Mundipharma the marketing, sales and distribution rights of Novartis ophthalmology medicines in Taiwan, according to a press release.

The deal follows similar agreements in the Philippines and Thailand.

“Mundipharma is constantly exploring opportunities to increase access to important medicines for the people who need them the most,” Mundipharma CEO Raman Singh said in the release. “This agreement with Novartis is an expansion of an already successful partnership between our two organizations and is another example of how we work with partners to leverage our unique distribution network to address unmet patient needs.”

Under the agreement, Novartis will retain all international development and clinical development responsibilities.